Christoph Thomssen

Summary

Affiliation: Martin Luther University
Country: Germany

Publications

  1. ncbi request reprint The prevalence of estrogen receptor-negative breast cancer in Ethiopia
    Eva Johanna Kantelhardt
    Department of Gynecology and Institute of Clinical Epidemiology, Martin Luther University, Ernst Grube Str, 40, 06097 Halle an der Saale, Germany
    BMC Cancer 14:895. 2014
  2. pmc Mammographic density and inter-observer variability of pathologic evaluation of core biopsies among women with mammographic abnormalities
    Pietro Trocchi
    Institute of Clinical Epidemiology, Martin Luther University Halle Wittenberg, Halle Saale, Magdeburger Str 8, Halle Saale 06097, Germany
    BMC Cancer 12:554. 2012
  3. ncbi request reprint First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study
    Christoph Thomssen
    Martin Luther Universitat Halle Wittenberg, Halle Saale, Germany
    Oncology 82:218-27. 2012
  4. pmc Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel
    Eva J Kantelhardt
    Klinik und Poliklinik für Gynäkologie, Martin Luther Universitat, Halle Saale, Germany
    BMC Cancer 11:140. 2011
  5. pmc Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer
    Volkmar Muller
    University Medical Center, Hamburg, Department of Gynecology, Martinistrasse 52, 20246 Hamburg, Germany
    BMC Cancer 10:430. 2010
  6. pmc Reliability and validity of needle biopsy evaluation of breast-abnormalities using the B-categorization--design and objectives of the Diagnosis Optimisation Study (DIOS)
    Alexander Kluttig
    Clinical Epidemiology Unit, Institute of Medical Epidemiology, Biometry and Informatics, University Halle Wittenberg, Halle Saale, Germany
    BMC Cancer 7:100. 2007

Collaborators

  • Ian Smith
  • Jean Yves Pierga
  • Kathleen I Pritchard
  • Laura Biganzoli
  • Bella Kaufman
  • Pietro Trocchi
  • Andreas Stang
  • Alexander Kluttig
  • Eva Johanna Kantelhardt
  • Martina Vetter
  • Eva J Kantelhardt
  • Marcus Schmidt
  • Volkmar Muller
  • Andrea Schmidt-Pokrzywniak
  • Solomon Bogale
  • Erdme Knauf
  • Anne Reeler
  • Tufa Gemechu
  • Assefa Mathewos
  • Bekuretsion Yonas
  • Abreha Aynalem
  • Tigeneh Wondemagegnehu
  • Ahmedin Jemal
  • Giske Ursin
  • Oliver Kuss
  • Thomas Löning
  • Werner Bocker
  • Hans Jürgen Holzhausen
  • Kathrin Ruschke
  • Doris Augustin
  • Nadia Harbeck
  • Corinne Veyret
  • Fred Sweep
  • Daniela Paepke
  • Fritz Jaenicke
  • Christoph Meisner
  • Pierre Marie Martin
  • Volker Hanf
  • Manfred Schmitt
  • Gunter von Minckwitz
  • Manfred Glados
  • Volker Heilmann
  • Volker Möbus
  • Henryk Borowicz
  • Christian Jackisch
  • Axel Hinke
  • Antje Lehnert
  • Tilmann Lantzsch
  • Christiane Taege
  • Steffen Hauptmann
  • Thomas Loening
  • Thomas Decker
  • Joerg Buchmann
  • Hans Juergen Holzhausen
  • Anke Heinig
  • Werner Boecker

Detail Information

Publications6

  1. ncbi request reprint The prevalence of estrogen receptor-negative breast cancer in Ethiopia
    Eva Johanna Kantelhardt
    Department of Gynecology and Institute of Clinical Epidemiology, Martin Luther University, Ernst Grube Str, 40, 06097 Halle an der Saale, Germany
    BMC Cancer 14:895. 2014
    ..In this paper, we provide the first report on the proportion of ER-negative BC in Ethiopia, and the relation to progesterone-receptor (PgR) status...
  2. pmc Mammographic density and inter-observer variability of pathologic evaluation of core biopsies among women with mammographic abnormalities
    Pietro Trocchi
    Institute of Clinical Epidemiology, Martin Luther University Halle Wittenberg, Halle Saale, Magdeburger Str 8, Halle Saale 06097, Germany
    BMC Cancer 12:554. 2012
    ..We measured the influence of mammographic density on the inter-observer variability of histopathological findings of breast biopsies...
  3. ncbi request reprint First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study
    Christoph Thomssen
    Martin Luther Universitat Halle Wittenberg, Halle Saale, Germany
    Oncology 82:218-27. 2012
    ..We conducted an exploratory analysis of patients with TNBC treated in the single-arm routine oncology practice ATHENA study...
  4. pmc Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel
    Eva J Kantelhardt
    Klinik und Poliklinik für Gynäkologie, Martin Luther Universitat, Halle Saale, Germany
    BMC Cancer 11:140. 2011
    ..High-risk node-negative patients should receive chemotherapy. Anthracycline-based regimens are accepted as a standard, the additional benefit of taxanes remains an open question...
  5. pmc Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer
    Volkmar Muller
    University Medical Center, Hamburg, Department of Gynecology, Martinistrasse 52, 20246 Hamburg, Germany
    BMC Cancer 10:430. 2010
    ....
  6. pmc Reliability and validity of needle biopsy evaluation of breast-abnormalities using the B-categorization--design and objectives of the Diagnosis Optimisation Study (DIOS)
    Alexander Kluttig
    Clinical Epidemiology Unit, Institute of Medical Epidemiology, Biometry and Informatics, University Halle Wittenberg, Halle Saale, Germany
    BMC Cancer 7:100. 2007
    ..This paper describes the design and objectives of the DIOS Study...